Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Junshi/Coherus Report PD-1 Effective in US Trial for Nasopharyngeal Carcinoma

publication date: Feb 16, 2023

Shanghai Junshi Bio and Coherus of Redwood City, CA reported their partnered PD-1 posted positive results in a US Phase III nasopharyngeal carcinoma trial. Toripalimab produced a statistically significant improvement in overall survival though details were not released. It was administered as a first-line therapy in combination with gemcitabine and cisplatin for recurrent or metastatic NPC. Two years ago, Coherus, a US company set up to in-license China drugs, paid $150 million upfront to acquire US-Canada rights to the PD-1 in a deal worth up to $1.1 billion. More details....

Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ: CHRS)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital